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Artemisinin resistance is rapidly spreading in Southeast Asia. The efficacy of artemisinin-combination 
therapy (ACT) continues to be excellent across Africa. We performed parasite transcriptional profiling 
and genotyping on samples from an antimalarial treatment trial in Uganda. We used qRT-PCR and 
genotyping to characterize residual circulating parasite populations after treatment with either ACT or 
ACT-primaquine. Transcripts suggestive of circulating ring stage parasites were present after treatment 
at a prevalence of >25% until at least 14 days post initiation of treatment. Greater than 98% of all ring 
stage parasites were cleared within the first 3 days, but subsequently persisted at low concentrations 
until day 14 after treatment. Genotyping demonstrated a significant decrease in multiplicity of infection 
within the first 2 days in both ACT and ACT-primaquine arms. However, multiple clone infections 
persisted until day 14 post treatment. Our data suggest the presence of genetically diverse persisting 
parasite populations after ACT treatment. Although we did not demonstrate clinical treatment failures 
after ACT and the viability and transmissibility of persisting ring stage parasites remain to be shown, 
these findings are of relevance for the interpretation of parasite clearance transmission dynamics and 
for monitoring drug effects in Plasmodium falciparum parasites.
Malaria remains a leading cause of global morbidity and mortality with approximately 584,000 deaths and 198 
million clinical cases of malaria in 20131. Prompt administration of effective antimalarial treatment remains a 
critical strategy for reducing the burden of malaria2,3. Artemisinin combination therapy (ACT) is universally 
recommended for uncomplicated P. falciparum malaria, and continued efficacy is crucial for successful elimina-
tion and eradication efforts. The high potency of artemisinins results in a rapid initial reduction of the biomass 
of asexual malaria parasites, while the more slowly eliminated partner drug contributes to parasite clearance and 
prevents subsequent recrudescent infections4,5. Despite the emergence and spread of parasites with a slow clearing 
phenotype after artesunate monotherapy across Southeast Asia, parasite clearance remains rapid in Africa with 
< 5% of patients being parasite positive by microscopy on day 3 after initiation of ACT treatment6,7. However, at 
least one third of patients may remain parasite positive by DNA-based molecular detection methods8,9. If this 
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DNA persistence reflects persistence of parasites following treatment, this may have implications for the likeli-
hood of onward malaria transmission to mosquitoes, the feasibility of elimination in low transmission settings, 
and for the evolution of drug resistant parasites.
The significance of DNA-based detection of residual parasitemia after ACT treatment is currently unknown. 
While residual submicroscopic parasitemia has been associated with subsequent recrudescence of infections8, a 
PCR signal may also be explained by residual circulating DNA molecules, or by the persistence of non-replicating 
mature gametocytes that can persist at low concentrations for several weeks after treatment8. The persistence 
of replicating or dormant asexual stage parasites after ACT treatment would have important implications for 
understanding mechanisms of drug action and the ability of parasites to tolerate drug treatment10,11. Here, we use 
a recently developed transcript-based qRT-PCR assay12 to sensitively detect and quantify asexual and gametocyte 
populations at submicroscopic levels after treatment with the ACT artemether-lumefantrine alone (AL) or in 
combination with the gametocytocidal drug primaquine (AL− PQ).
Results
Persistence of RNA transcripts suggestive of circulating ring and mature gametocyte stages. 
In the original analysis of samples analyzed in the AL or AL− PQ treatment arms of the study, total parasitemia 
and presence of gametocytes were determined by microscopy, and Pfs25 QT-NASBA was used for mature 
gametocyte detection. This analysis demonstrated complete clearance of patent parasitemia at day 3 in both 
treatment arms, and clearance of mature gametocyte transcripts in 94% of patients by day 14 upon primaquine 
treatment13. Using a recently developed and highly sensitive qRT-PCR assay for stage-specific detection of P. falci-
parum parasites12, we were able to confirm the persistence of mature gametocytes upon AL treatment and efficient 
clearance with the addition of 0.75 mg/kg primaquine (Fig. 1A and S2). Surprisingly, however, we also observed 
the presence of RNA transcripts suggestive of ring stage parasites at a prevalence of > 25% until day 14 in both 
treatment arms (Fig. 1B). Estimates of parasite numbers using regression analysis based on data points with both 
microscopic and qRT-PCR detection of parasite stages (Fig. S1A) demonstrated reduction of the concentration 
of ring stages by > 98% within the first 3 days of treatment but persistence at low levels until day 14 (Fig. 2B). 
Differential reduction in ring versus mature gametocyte loads upon treatment (Fig. 2A,B) resulted in an increase 
in the fraction of all parasites that were mature gametocytes. This fraction rose from < 0.4% on day 0 to 20% on 
day 3 in the AL arm, and from 0.1 to 8.1% in the same time frame in the AL-PQ arm (Fig. 2C). We have previously 
demonstrated that the mature gametocyte marker is not expressed in ring stage parasites12, and although the ring 
stage marker is not exclusively expressed in the ring stage, we performed cellular sensitivity analysis across the 
parasite cycle for the ring stage marker, and showed that the observed signal of this marker could not originate 
from mature gametocytes in the patient samples (Fig. S1B). This hypothesis is supported by the lack of any sig-
nificant correlation between the prevalence of ring stage marker and either PF3D7_1438800 or Pfs25 (from the 
QT-NASBA data) across patient samples and treatment arms. In contrast the two different gametocyte markers 
are highly correlated in the AL group (p-value = 2.2 × 10−14) and in the AL-PQ group (p-value = 3.2 × 10−5), 
and in the subset of persisting parasites in both groups (p-value = 1.1 × 10−18), using a partial correlation test 
controlling for the time of sampling. Together these data suggest the existence of low-level persistent ring stage 
parasites upon AL treatment, alone or in combination with primaquine, among African malaria patients from 
Uganda.
Figure 1. Changes in asexual and sexual stage parasite prevalence over time. (A) The prevalence of mature 
gametocytes (MG, PF3D7_1438800) decreases more rapidly in the AL-PQ group (the slope of simple linear 
regression = − 0.0045 (95% CI = [− 0.014, 0.0047]) for the AL group and − 0.040 [95% CI = [− 0.049, − 0.032] 
for the AL + PQ group). (B) The prevalence of rings (PF3D7_0501300) through time is similar in the AL group 
and the AL + PQ group (the slope of simple linear regression = − 0.040 (95% CI = [− 0.057, − 0.023]) for the AL 
group and − 0.042 [95% CI = [− 0.054, − 0.029] for the AL + PQ group).
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Genotypic analysis of persisting ring stage parasites. The observed presence of a low level reservoir 
of circulating ring stage parasites at day 14 demonstrated that these parasites persisted after a fully observed cura-
tive dose of AL. To determine possible selection of parasite subpopulations upon treatment we performed msp2 
genotyping (Fig. 3). We found that multiplicity of infection (MOI) decreased significantly in both the AL and the 
AL-PQ arms between day 0 and day 3 (Mann-Whitney Test, p-value = 0.05 and 0.02, respectively), however many 
of them remained > 1 (Fig. 3A,B). Interestingly, a subset of msp2 genotypes was significantly enriched in the per-
sistent parasite population (Table S1). We also found that in several children the total number of msp2 genotypes 
detected during follow-up was greater than the maximum MOI for any given day (Fig. 3C), suggesting some 
dynamics in the composition of the parasite population at later days post treatment. In 88.2% (16/18) of patients 
with successful msp2 genotyping of persisting parasites on day 14 and all preceding days, the parasite genotypes 
on day 14 were also detected on preceding days. This indicates that re-infections were uncommon during the first 
14 days of follow-up14 and the vast majority of parasites detected on day 14 were already present at enrollment. 
Similar analyses using a recently developed molecular barcode tool15 found a high proportion of polyallelic calls 
in the barcode (Fig. 4A,B) and that the major barcode alleles changed across the time of infection, suggesting that 
multiple clones are circulating in the patients and that the dominant genotype can fluctuate over time.
Residual ring stage parasitemia by day 3 was not significantly associated with patient age (medians are 4 
[cleared] and 4.5 [residual], Mann-Whitney Test p-value = 0.70), enrollment parasite density (medians are 23,950 
[cleared] and 26,670 [residual], Mann-Whitney Test p-value = 0.45) or any other patient or infection charac-
teristics (Table 1). Similarly, residual ring stage parasitemia by day 14 was not associated with these patient or 
infection characteristics (Table S2). The proportion of individuals with gametocytes by microscopy, QT-NASBA 
Figure 2. Changes in ring stage and mature gametocyte stages through time. (A) The number of mature 
gametocytes after day 3 is significantly smaller in the AL + PQ group (p-value = 0.0057). (B) The number 
of rings decreases between day 0 and day 3, and the level of the decrease is similar in the AL group and the 
AL + PQ group (p-value = 0.18). (C) The proportion of the total parasite population that represents mature 
gametocytes increases during follow-up (Mann-Whitney test, p-values = 7.92 × 10−10 [AL] and 1.01 × 10−7 
[AL + PQ]).
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or multiplexed qRT-PCR, at day 0 was not associated with residual ring stage parasitemia (Fisher’s Exact Test, 
p-values are 0.70 [microscopy], 0.61 [QT-NASBA], and 0.44 [qRT-PCR]).
Discussion
Using a multiplexed qRT-PCR assay for stage-specific detection of P. falciparum mRNA transcripts, we provide 
evidence of persisting submicroscopic densities of ring stage parasites after successful treatment with either AL 
alone or plus primaquine. While parasite densities and the estimated number of clones in infections were reduced 
in the first 3 days after treatment9, more than 25% of the patients harbored low-density parasite populations based 
on stage-specific transcript quantification, that were frequently clonally complex and persisted for at least 14 days 
after initiation of treatment. Transcripts of our ring marker disappear after radical cure of experimental infections 
in human volunteers; when subcurative doses are administered and recrudescent infection occurs, ring marker 
transcripts reappear in the blood coincidentally with recrudescence (James McCarthy, personal communication). 
Although the dynamics of transcript clearance may be different in naturally exposed malaria-infected individuals 
who have clonally complex infections, non-synchronous infections and pre-exiting immunity, our findings sug-
gest the persistence of very low concentrations of ring-stage parasites after apparently successful ACT treatment.
The role of persisting submicroscopic infections in determining treatment outcome, transmission dynam-
ics and possibly drug resistance remains to be established. Previous studies on continued PCR positivity after 
ACT treatment were unable to reliably differentiate between residual circulating DNA molecules or gameto-
cytes8,9,16,17. Our analysis based on stage specific mRNA transcripts, overcomes the uncertainties of DNA-based 
assays. Although our findings fall short of conclusively showing that RNA transcripts represent viable parasites, 
Figure 3. MSP2 genotyping to determine multiplicity of infection. (A,B) MOI decreases after treatment 
in both groups (Mann-Whitney test, p-values = 0.0016 [AL] and 0.0081 [AL + PQ]). Instead of having one 
dominant genotype, multiple genotypes are circulating on later days in some samples. One patient sample has 
MOI = 11 on day 0 in the AL group and is not shown in the figure. (C) Total number of msp2 types is greater 
than maximum MOI in some patients, indicating that new genotypes emerge later in the patients.
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they may shed new light on parasite clearance dynamics after ACT treatment. Parasite carriage has been reported 
to persist for several months in a fraction of chloroquine-treated patients18,19. This chronic carriage is predomi-
nantly submicrosopic, only rarely being detectable by microscopy, and associated with continued gametocyte pro-
duction18,19. It is conceivable that also after AL a fraction of patients may continue to harbor viable parasites that 
persist as chronic infections. In our study, the apparent persistence of ring stage parasites was not associated with 
gametocyte carriage or later recurrent parasite carriage, as recrudescence was only detected in 3.7% of patients13. 
We therefore did not observe direct consequences of residual ring stage parasitemia in terms of clinical response 
or transmission potential during the 28 days of follow-up. This also means that we did not provide conclusive 
evidence on the viability of the parasite populations that we detect based on ring-stage RNA. Studies that involve 
monitoring parasite populations for a longer period of follow-up or studies that attempt to culture very low par-
asite densities that persist after treatment may provide more definitive evidence for the viability and relevance of 
the parasite populations we detected. Our findings may also reflect a normal but previously unknown process of 
slow clearing, submicroscopic parasite populations that is specific to ACT treatment.
We hypothesized that increasing age, being an indicator of higher cumulative malaria exposure and thus 
immunity, would be associated with faster clearance of infections20. However, we observed persistence of rings 
among all ages (1 to 10 years), and there was no significant difference in age between patients with cleared and 
residual parasitemia. We observed that the number of rings at day 0 decreases with age, while neither the number 
of mature gametocytes nor MOI at day 0 change with age (Fig. S3). These observations suggest that age and there-
fore increasing exposure protects from high (asexual) parasite burden but not from gametocyte burden. Hence, 
the proportion of the total parasite population that represents mature gametocytes increases with age (irrespec-
tive of treatment), consistent with previous studies using microscopy or QT-NASBA data21,22.
Figure 4. Molecular barcode analysis to determine multiplicity of infection. (A,B) Highly polymorphic 
molecular barcodes suggest that multiple genotypes are circulating both before and after treatment.
Cleared 
parasitemia
Residual 
parasitemia p-value
Number of patients (day 3) 9 61
Number of patients (day 14) 55 15
Age 4 4.5 0.70
Gender (male:female) 5:4 27:34 0.72
Asexual parasite densityφ by 
microscopy at enrollment 23950 26670 0.45
Gametocyte prevalence by 
microscopy at enrollment 50% 37% 0.70
Gametocyte prevalence by 
microscopy at day 7 0 7.84% 1
Treatment, % AL + PQ treated 44% 49% 1
MOI at enrollment 1.5 2 0.38
Table 1.  Characteristics of cleared and residual parasitemia*. φ Unit of parasite density is the number of 
parasites per μl. *Medians are shown.
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The estimated ring stage parasite concentrations were very low beyond day 3 after initiation of treatment, with 
values below 2% of the original parasite density8. The precision of individual parasite densities is limited at these 
low concentrations, illustrated by our mean estimated densities of ~200 parasites/μ l at day 3, which, although 
not detected by microscopy in our study, should be detectable by an expert microscopist. A better quantifica-
tion of low parasite densities requires model optimization that would benefit from a larger number of natural 
low-density infections with asexual parasite quantification by qRT-PCR and microscopy to take into account 
possible variation in transcript numbers between parasite strains.
The reason for the persistence of parasite transcripts that is suggestive of ring-stage persistence, after appar-
ently successful treatment is unknown. Low levels of persisting parasites might originate from dormant parasite 
populations or a sequestered reservoir, might represent remaining parasites during therapy due to therapeutic 
pharmacokinetic properties, or might be associated with resistance to drugs. We observed no evidence of an asso-
ciation with drug resistance, parasitological and clinical cure rates by microscopy were excellent13, as is reported 
elsewhere in Uganda23,24. If the persistence would be due to drug resistance, only drug-resistant lineages could 
persist and we expect to observe low MOI and similar parasites that are persisting. However, although MOI 
decreased after treatment, many MOIs were greater than one (Fig. 3A,B), the major barcode changed through 
time, and persisting parasites have very diverse msp2 types (although two msp2 types are enriched among per-
sisting parasite populations). The detection of msp2 genotypes at individual time points is imperfect and influ-
enced by parasite densities, sequestration patterns and differences in amplification efficiency of smaller and larger 
msp2 alleles25. Although this may have influenced the accuracy of MOI estimates at individual time points, it is 
unlikely to have affected comparisons between treatment arms and a decline in MOI over time, or persistence of 
certain genotypes. Overall, our findings suggest that ring persistence is not caused by drug resistance selection on 
a particular genetic background. In vitro studies have revealed that parasites may be able to tolerate artemisinin 
treatment by entering a temporarily growth-arrested state of dormancy10 from which a fraction may recover. If 
the persisting ring stage parasites in our population reflect such dormant parasite populations, re-treatment of 
individuals with the same drug may be equally efficacious26 and ring stage parasite persistence should not be 
seen as an indicator of parasite resistance or clinically relevant altered clearance dynamics. Persisting ring stage 
parasites may also originate from a sequestered reservoir that is partially protected from drug treatment. Recent 
identification of the human bone marrow as a reservoir for parasite sequestration and gametocyte development27 
supports this hypothesis and would explain our finding of newly appearing genotypes during follow up; this may 
also be associated with the imperfect detectability of individual parasite clones28(Fig. 2A). We observed that the 
majority of these new clones appeared in the first week after initiation of treatment, reinforcing previous obser-
vations that re-infections are unlikely within the first 14 days after AL14, and suggesting that they are an unlikely 
explanation for the observed long persistence of ring stage parasites in our study.
In summary, we present preliminary evidence for persisting submicroscopic parasite populations that com-
prise ring stage parasites and gametocytes after treatment with AL or AL-PQ, treatment combinations that were 
efficacious in preventing recurrent parasite carriage by microscopy for at least 28 days. While the viability of these 
parasite populations remains to be established and we observed no evidence that parasite populations have no 
immediate clinical consequences for the treated patients, our findings are relevant for the interpretation of par-
asite clearance and transmission dynamics. Future in vivo studies are needed to confirm that the persistence of 
transcripts of ring stage parasites indicate viable parasite populations. These studies should be designed to deter-
mine whether the phenomenon of ring stage persistence is a characteristic of ACT treatment and allow for the 
assessment of late recrudescent infections and/or de novo generation of gametocytes from low levels of persisting 
parasite populations.
Methods
Ethics statement. All experiments were performed in accordance with relevant guidelines and regula-
tions. Specifically samples for this study were derived from a previously published randomized, double blind, 
placebo-controlled trial with four treatment arms13. This study was approved by Makerere University School 
of Medicine (2011–210), the Uganda National Council of Science and Technology (HS1056), and the London 
School of Hygiene and Tropical Medicine (5987) and was registered at ClinicalTrials.gov (NCT01365598). 
Informed consent was obtained from all subjects, and all samples were made anonymous for analysis.
Study cohort. Children aged 1–10 years with uncomplicated P. falciparum mono-infection with a parasite 
density lower than 500,000 parasites per μL, normal G6PD enzyme function and hemoglobin concentration ≥ 
80 g/L were randomized to treatment with AL alone (AL group) or in combination with 0.1, 0.4 or 0.75 mg/kg 
primaquine (AL-PQ group). For the current analysis, we selected 37 children from the AL arm and 33 children 
from the AL-PQ arm with a dose of 0.75 mg/kg primaquine, using random tables generated in Stata (version 
12.0). Children were followed for 28 days for safety parameters, recrudescence or re-infection. Blood samples 
were obtained by finger prick on days 0, 3, 7, 10 and 14 after initiation of treatment, and immediately transferred 
to L6 buffer (Severn Biotech Limited, Kidderminster, UK) and stored at − 80 °C until extraction. Nucleic acid 
material was extracted from 50 μ L aliquots using Total Nucleic Acid Isolation Kits–High Performance (Roche 
Applied Science, Mannheim, Germany) and a MagNA Pure LC automated extractor (Roche Applied Science).
Molecular detection of parasite stages. The patient’s parasite burden was quantified using micros-
copy, gametocyte detection by Pfs25 mRNA quantitative nucleic acid sequence based amplification13 and with a 
highly sensitive stage-specific qRT-PCR assay, as described previously12. The latter assay combines stage-specific 
markers to quantify the relative abundance of asexual and sexual P. falciparum parasites from patient samples 
using probe-based qRT-PCR. Reverse transcription was performed from extracted nuclear acid samples using 
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SuperScript III First-Strand Synthesis System (Life Technologies, Carlsbad, CA). Custom primers (Integrated 
DNA Technologies, Coralville, IA) and Taqman probes (Life Technologies) were used at 900 nM and 250 nM 
final concentrations, respectively, to measure the transcript levels of PF3D7_0501300 (previous accession num-
ber PFE0065w; for ring stage parasites), PF3D7_1438800 (PF14_0367; for mature gametocyte parasites) and 
PF3D7_1120200 (PF11_0209; as a constitutive parasite marker) on a Viia7 qRT-PCR machine (Life Technologies).
A linear regression model was developed to estimate the density of circulating ring and mature gametocyte 
parasites. We used the patient’s patent parasitemia (i.e., density of ring and mature gametocyte stages) obtained 
using Giemsa stained microscopy slide to define the relationship between parasite density and CT values from 
qRT-PCR (ring and mature gametocyte marker, respectively) by regression analysis. The regression between 
microscopy and qRT-PCR was then used to infer parasite density in the remainder of the data points with 
sub-patent parasite levels (Fig. S1A). Multiple linear regressions were used to test the difference in parasite density 
in the AL and the AL + PQ groups while controlling for the day on which the samples were collected.
To determine the sensitivity of our ring marker detection by qRT-PCR assay, we performed a cellular dilution 
experiment under controlled in vitro conditions with stage-specific populations of P. falciparum strain 3D7 (Fig. S1B). 
Parasites were cultured in human type O+ red blood cells (Research Blood Components, Boston, MA) diluted 
to 4% hematocrit in RPMI-1640 medium (Sigma-Aldrich, St. Louis MO) supplemented with 10% human serum 
(Interstate Blood Bank, Memphis, TN), 25 mM HEPES (EMD Biosciences), sodium bicarbonate (Sigma), and 
hypoxanthine (Sigma), as described previously29. Parasite cultures were maintained at 37 °C in an atmosphere of 
1% O2 and 5% CO, 94% N2. The parasites were synchronized with 5% D-sorbitol, and time points were collected 
for pure stage-specific populations at 8, 16, 24, 32, 40 hours post invasion for asexual parasite stages, and days 2, 
4, and 7 post gametocyte induction using partially spent (“conditioned”) medium for sexual parasite stages30,31. 
Serial dilutions of purified red blood cells (RBC) infected synchronized populations of the above parasite stages 
were made into uninfected RBCs, and RNA was extracted using Trizol (Life Technologies) and RNeasy (Qiagen, 
Valencia, CA) for subsequent cDNA synthesis and qRT-PCR as described above.
Multiplicity of infection and genotyping analysis. DNA from all time points was tested for clonal 
complexity based on genotyping for the polymorphic marker gene merozoite surface protein 2 (msp2) using 
capillary electrophoresis for fragment sizing32 following chelex-saponin extraction from filter papers (Whatman 
3 MM, Maidstone, UK). Results were analyzed with Peak Scanner version 1.0 (Applied Biosystems) with dis-
crete peaks being interpreted as unique clones, after adjustment for background levels per experiment. Nucleic 
acids from the whole blood samples in L6 buffer that were extracted by MagNA Pure LC automated extractor, 
as described above, were further analyzed using previously described molecular barcode methods15. Briefly, 1 μ 
L of each extracted sample was preamplified33 in 20 μ L reactions using the TaqMan Preamp Master Mix for 14 
cycles according to manufacturer’s directions (Applied Biosystems) using 0.2× pooled TaqMan barcoding assays. 
Samples were diluted 1:20 and 5 μ L each preamplified product used for the molecular barcode. TaqMan barcod-
ing assays were run on a ViiA system (Applied Biosystems) and genotypes called using the pre-installed analysis 
software.
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